This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haskell, C. M. Articles by Sullivan, A. Search for Related Content PubMed PubMed Citation Articles by Haskell, C. M. Articles by Sullivan, A.

Comparative Survival in Tissue Culture of Normal and Neoplastic Human Cells Exposed to Adriamycin¹

Departments of Surgery and Medicine, University of California School of Medicine, Los Angeles, California 90024 [C.M.H., A.S.], and the Surgical Services, Sepulveda Veterans Administration Hospital, Sepulveda, California 91343 [C. M. H.]

In an effort to develop an in vitro predictive test for the clinical usefulness of adriamycin, we have grown human cells derived from normal tissue (skin, muscle, and Girardi heart cells) and human neoplastic cells in tissue culture and exposed them to varying concentrations of adriamycin for 1, 24, 48, and 72 hr. Cardiac cells were extremely sensitive to adriamycin; lesser degrees of inhibition were seen in order of decreasing sensitivity by sarcoma and melanoma cells, normal muscle, and normal skin fibroblasts. The relative sensitivity of tissues correlated in a general way with clinical experience; however, the in vitro test results in two patients treated with adriamycin did not correlate with their clinical course. Although our findings in vitro were not useful clinically, we suggest that further study of human cardiac cells in tissue culture may improve our understanding of adriamycin cardiotoxicity.

¹ Supported in part by USPHS Research Grants CA 12582 and CA 05262, a grant from the California Institute for Cancer Research, and research funds of the Veterans Administration.

² To whom correspondence should be addressed, at the Department of Medicine, University of California at Los Angeles School of Medicine, Los Angeles, Calif. 90024.

Received 6/ 7/74. Accepted 8/ 5/74.

This article has been cited by other articles:

				S. E. Lipshultz, A. L. Giantris, S. R. Lipsitz, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, et al. Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol J. Clin. Oncol., March 15, 2002; 20(6): 1677 - 1682. [Abstract] [Full Text] [PDF]